Activating NFE2L2 mutations or mutations in KEAP1, which normally targets NFE2L2 for degradation, have been shown to predict an increased risk of local failure after radiotherapy but not surgery for lung cancer [35,38]. This evidence concerns the gene NFE2L2 and lung carcinoma.